Tamoxifen to raloxifene and beyond

Area of Science:

• Oncology
• Pharmacology
• Endocrinology

Background:

• Selective estrogen receptor modulators (SERMs) like tamoxifen are standard for hormone-responsive breast cancer and prevention in high-risk women.
• Tamoxifen exhibits antiestrogenic effects on breast tissue but partial estrogenic effects on bone, lipids, and the central nervous system, causing side effects like hot flashes and increasing endometrial cancer risk.
• Raloxifene, another SERM, is approved for osteoporosis prevention and also shows promise in breast cancer prevention without increasing endometrial cancer incidence.

Purpose of the Study:

• To compare the efficacy of tamoxifen and raloxifene in breast cancer prevention.
• To evaluate and compare the risks associated with tamoxifen and raloxifene, focusing on endometrial cancer incidence.
• To inform the development of novel agents with improved therapeutic profiles.

Main Methods:

• The Study of Tamoxifen and Raloxifene (STAR) trial is a pivotal clinical trial comparing tamoxifen and raloxifene.
• Participants include women at high risk for breast cancer and/or osteoporosis.
• Data collection focuses on breast cancer incidence, endometrial cancer risk, bone health, and menopausal symptoms.

Main Results:

• Tamoxifen is effective in breast cancer prevention but carries an increased risk of endometrial cancer and side effects like hot flashes.
• Raloxifene demonstrates efficacy in breast cancer prevention with a lower risk of endometrial cancer compared to tamoxifen.
• Both agents show benefits for bone health and lipid profiles in postmenopausal women.

Conclusions:

• Both tamoxifen and raloxifene are effective in preventing breast cancer in high-risk women.
• Raloxifene offers a potentially safer alternative to tamoxifen due to a lower risk of endometrial cancer.
• Ongoing research aims to identify ideal agents with targeted estrogenic and antiestrogenic effects for improved breast cancer and osteoporosis management.